Gainers
- Aptorum Group Limited (NASDAQ:APM) shares rose 94.4% to $3.15 in pre-market trading after gaining around 10% on Monday. The FDA recently granted Orphan Drug Designation to Aptorum Group’s SACT-1, a repurposed small molecule compound for Neuroblastoma.
- Esports Entertainment Group, Inc. (NASDAQ:GMBL) rose 16.1% to $3.17 in pre-market trading. Esports Entertainment, on Monday, received an order approving a transactional waiver from the Director of the New Jersey Division of Gaming Enforcement, permitting the company to begin accepting bets in the state.
- BT Brands, Inc. (NASDAQ:BTBD) rose 8.1% to $3.35 in pre-market trading after climbing around 28% on Monday.
- Kintara Therapeutics, Inc. (NASDAQ:KTRA) rose 8% to $0.3995 in pre-market trading after declining more than 6% on Monday.
- Innate Pharma S.A. (NASDAQ:IPHA) shares rose 8% to $4.01 in pre-market trading following a 10% drop on Monday.
- Logitech International S.A. (NASDAQ:LOGI) rose 7.5% to $80.01 in pre-market trading as the company posted upbeat quarterly results and raised fiscal 2022 forecast.
- WISeKey International Holding AG (NASDAQ:WKEY) shares rose 7.2% to $3.69 in pre-market trading.
- Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC) rose 7% to $11.66 in pre-market trading after reporting upbeat core earnings for its fourth quarter.
- Zosano Pharma Corporation (NASDAQ:ZSAN) rose 6.4% to $0.5080 in pre-market trading. Zosano Pharma, on January 18, resubmitted its M207 (Zolmitriptan Transdermal Microneedle System) 505(B)(2) NDA to the FDA.
- International Business Machines Corporation (NYSE:IBM) rose 2.8% to $132.40 in pre-market trading after the company reported better-than-expected fourth-quarter EPS and sales results.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Check out these penny stocks insiders are buying
Losers
- Vaxxinity, Inc. (NASDAQ:VAXX) shares fell 13.4% to $7.44 in pre-market trading after gaining more than 5% on Monday. Vaxxinity recently said the first Parkinson's disease patient was dosed in Part B of a Phase 1 clinical trial of UB-312.
- Pulmatrix, Inc. (NASDAQ:PULM) shares fell 10.5% to $0.35 in pre-market trading. Pulmatrix, last month, announced a $6.75 million registered direct offering.
- Blue Star Foods Corp. (NASDAQ:BSFC) shares fell 10.5% to $3.55 in pre-market trading after gaining around 5% on Monday.
- Brickell Biotech, Inc. (NASDAQ:BBI) shares fell 8.5% to $0.2116 in pre-market trading. HC Wainwright & Co recently initiated coverage on the stock with a Buy rating and $2 price target.
- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) fell 8.5% to $1.07 in pre-market trading after gaining around 5% on Monday.
- TCR2 Therapeutics Inc. (NASDAQ:TCRR) fell 7.3% to $3.30 in pre-market trading. Goldman Sachs, last week, downgraded TCR2 Therapeutics from Buy to Neutral and lowered the price target from $28 to $5.
- Pintec Technology Holdings Limited (NASDAQ:PT) fell 6.4% to $0.6161 in pre-market trading after dipping more than 52% on Monday.
- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) shares fell 6.4% to $1.76 in pre-market trading. HC Wainwright & Co, on Monday, initiated coverage on Reviva Pharmaceuticals with a Buy rating and announced a price target of $10.
- Ocugen, Inc. (NASDAQ:OCGN) fell 5.4% to $3.14 in pre-market trading. Ocugen, on Monday, named Nirdosh Jagota, Ph.D., as Senior Vice President (SVP), Regulatory Affairs, compliance and safety.
- Society Pass Incorporated (NASDAQ:SOPA) fell 5.3% to $5.00 in pre-market trading.
